Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
VERU's Shares Jump on Successful COVID-19 Study Results
03:44pm, Friday, 08'th Jul 2022 Zacks Investment Research
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
VERU's Shares Jump on Successful COVID-19 Study Results
01:13pm, Friday, 08'th Jul 2022
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Zacks Market Edge Highlights: ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General Mills
12:19pm, Thursday, 07'th Jul 2022 Zacks Investment Research
ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General Mills are part of Zacks Market Edge blog.
Q2 Earnings: Energy and What Else?
07:33pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Expectations are low for this earnings season. Will companies surprise the Street?
6 Fallen Angel Stocks to Buy Now Will Continue to Pay Fat Dividends
07:20am, Wednesday, 06'th Jul 2022
Finding stocks that are trading down after the worst first half for the S&P 500 in over 50 years is not hard these days.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
09:50pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
Gilead Sciences (GILD) closed the most recent trading day at $62.34, moving -0.03% from the previous trading session.
What Stocks To Buy Today? 5 Health Care Stocks To Know
04:30pm, Tuesday, 05'th Jul 2022
Could health care stocks be the best stocks to jump on in the second half of 2022?
Is Gilead Sciences' Dividend Safe?
11:00am, Monday, 04'th Jul 2022 The Motley Fool
Or is this biotech a dividend trap?
Should You Invest in the iShares Biotechnology ETF (IBB)?
10:20am, Monday, 04'th Jul 2022 Zacks Investment Research
Sector ETF report for IBB
Is Gilead Sciences' Dividend Safe?
07:00am, Monday, 04'th Jul 2022
Or is this biotech a dividend trap?
Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill
02:56pm, Friday, 01'st Jul 2022 Zacks Investment Research
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
03:51pm, Wednesday, 29'th Jun 2022 Zacks Investment Research
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
02:28pm, Wednesday, 29'th Jun 2022 Zacks Investment Research
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
11:36am, Wednesday, 29'th Jun 2022
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Gilead Sciences (GILD) Stock Moves -0.99%: What You Should Know
09:50pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
Gilead Sciences (GILD) closed at $62.21 in the latest trading session, marking a -0.99% move from the prior day.
